Alemtuzumab use in relapsed and refractory chronic lymphocytic leukemia: a history and discussion of future rational use

由 Warner, Jeremy L., Arnason, Jon E.
出版 2012

B cell receptor pathway in chronic lymphocytic leukemia: specific role of CC-292

由 Arnason, Jon E, Brown, Jennifer R
發表在 Immunotargets Ther (2014)

Efficacy results of a phase 2 trial of first-line idelalisib plus ofatumumab in chronic lymphocytic leukemia

由 Lampson, Benjamin L., Kim, Haesook T., Davids, Matthew S., Abramson, Jeremy S., Freedman, Arnold S., Jacobson, Caron A., Armand, Philippe A., Joyce, Robin M., Arnason, Jon E., Rassenti, Laura Z., Kipps, Thomas J., Fein, Joshua, Fernandes, Stacey M., Hanna, John R., Fisher, David C., Brown, Jennifer R.
發表在 Blood Adv (2019)

UMBRALISIB IN COMBINATION WITH IBRUTINIB IN PATIENTS WITH RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKAEMIA OR MANTLE CELL LYMPHOMA: A MULTICENTRE PHASE 1–1B STUDY.

由 Davids, Matthew S., Kim, Haesook T., Nicotra, Alyssa, Savell, Alexandra, Francoeur, Karen, Hellman, Jeffrey M., Bazemore, Josie, Miskin, Hari P., Sportelli, Peter, Stampleman, Laura, Maegawa, Rodrigo, Rueter, Jens, Boruchov, Adam M., Arnason, Jon E, Jacobson, Caron A., Jacobsen, Eric, Fisher, David C., Brown, Jennifer R.
發表在 Lancet Haematol (2018)

Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity

由 Lampson, Benjamin L., Kasar, Siddha N., Matos, Tiago R., Morgan, Elizabeth A., Rassenti, Laura, Davids, Matthew S., Fisher, David C., Freedman, Arnold S., Jacobson, Caron A., Armand, Philippe, Abramson, Jeremy S., Arnason, Jon E., Kipps, Thomas J., Fein, Joshua, Fernandes, Stacey, Hanna, John, Ritz, Jerome, Kim, Haesook T., Brown, Jennifer R.
發表在 Blood (2016)